Gene Therapy Market (2026-2036)

The growth of this market is mainly driven by the high unmet need in genetic and rare diseases, the expansion of approved gene therapies into broader patient populations and new regions, the maturation of gene editing into commercial medicines, and supportive regulatory frameworks that accelerate development for rare conditions. However, serious safety events associated with high-dose viral vectors, very high one-time prices and payer budget impact, complex and costly vector manufacturing, and slow commercial uptake that has led several companies to exit or restructure restrain the growth of this market.

Furthermore, in vivo gene editing, redosable and locally delivered gene therapies, and outcomes-based payment models are expected to offer growth opportunities for the stakeholders in this market. However, long and complex patient journeys through qualified treatment centers, durability and immunity questions, the evidentiary demands of small patient populations, and uneven global access remain major challenges impacting the growth of this market. Additionally, the shift from narrow to broad labels through new routes of administration, the rise of bespoke and platform-based gene editing, the expansion of gene therapies into the Middle East and Asia, and consolidation and restructuring across the gene therapy industry are prominent trends in this market.

The Gene Therapy Market comprises approved medicines that treat or prevent disease by adding, replacing, silencing, or editing genetic material in a patient's cells. The market covers in vivo gene therapies, in which a vector carrying genetic material is delivered directly into the body, and ex vivo gene therapies, in which a patient's hematopoietic stem cells are collected, genetically modified or edited outside the body, and reinfused. It spans delivery vectors, including adeno-associated virus (AAV), lentiviral, herpes simplex virus type 1 (HSV-1), adenoviral and oncolytic vectors, and non-viral systems such as lipid nanoparticles; modalities, including gene addition, gene editing using CRISPR nucleases, base editors, and prime editors, and oncolytic and suicide gene therapies; and routes of administration, including intravenous, intrathecal, subretinal, topical, intravesical, and intraparenchymal delivery. Therapeutic areas include neuromuscular diseases, hemoglobinopathies and hemophilia, inherited retinal diseases, genetic skin disorders, metabolic and lysosomal diseases, oncology, and central nervous system disorders. Market value is measured at manufacturer net sales of approved gene therapies. Chimeric antigen receptor T-cell therapies and other gene-modified immune cell therapies are excluded and analyzed in separate reports. The ecosystem spans gene therapy developers, vector and gene editing platform companies, contract development and manufacturing organizations, qualified treatment centers, payers, patient organizations, and regulators.

Gene therapy has established a commercial foundation built on a small number of high-value products. Sarepta's Elevidys generated USD 898.7 million in 2025 net product revenue and has been administered to more than 1,100 patients worldwide, and Novartis' Zolgensma, a one-time AAV therapy for spinal muscular atrophy, generated USD 307 million in the fourth quarter of 2025, up 17%, reflecting strong demand in newly diagnosed patients. Krystal Biotech's Vyjuvek, a topical, redosable HSV-1-based gene therapy for dystrophic epidermolysis bullosa, generated net revenue of USD 388 million to USD 389 million in 2025, following launches in Europe and Japan. Other approved therapies include CSL's Hemgenix for hemophilia B, Spark and Roche's Luxturna for inherited retinal disease, Ferring's Adstiladrin for bladder cancer, PTC Therapeutics' Kebilidi for AADC deficiency, and Orchard Therapeutics' Lenmeldy for metachromatic leukodystrophy.

Gene editing has moved from the laboratory to the clinic and market. Vertex and CRISPR Therapeutics' Casgevy, approved in the U.S. in late 2023 for sickle cell disease and in 2024 for transfusion-dependent beta-thalassemia, generated USD 115.8 million in 2025 revenue, up from USD 10.0 million in 2024, as 64 patients were infused in 2025 compared with 5 in 2024, and it is available in the U.S., the U.K., the EU, Saudi Arabia, Qatar, and other markets. Casgevy carries a U.S. wholesale acquisition cost of USD 2.2 million, while the competing lentiviral gene therapy Lyfgenia, from Genetix Biotherapeutics, formerly bluebird bio, is priced at USD 3.1 million. Indications are also broadening: the FDA approved Itvisma, an intrathecal form of Zolgensma, in November 2025 for patients aged 2 years and older, and Novartis reported that Itvisma was approved in both the U.S. and the UAE in the fourth quarter of 2025, with the first patients treated in the UAE.

The industry is also navigating significant setbacks. In 2025, deaths from acute liver failure in non-ambulatory patients treated with Elevidys led the FDA to restrict its use to ambulatory patients aged 4 years and older and, in November 2025, to add a boxed warning for acute serious liver injury and acute liver failure, and several companies have exited, divested, or restructured gene therapy programs amid slow uptake and high costs. Nevertheless, with an estimated 7,000 rare diseases, about 80% of which have a genetic cause, and new routes, gene editing platforms, and payment models expanding the treatable population, the market is expected to grow substantially through 2036.